US EditionOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
- Oncolytics Biotech Inc. And Alumni Capital LP entered a share purchase agreement on April 10, 2025.
- Oncolytics needs funding to progress pelareorep toward clinical milestones, minimizing shareholder dilution.
- The agreement lets Oncolytics sell common stock to Alumni over 15 months.
- Alumni must purchase up to $20 million of common stock, with no warrants or derivatives.
- Oncolytics issued 816,326 commitment shares to Alumni; shares got conditional TSX approval.
24 Articles
24 Articles
Hanford Sentinel
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an…
Small-cap cancer therapy innovator raises $20M in flexible funding
Oncolytics Biotech (TSX:ONC), a clinical-stage cancer therapy company, announced a US$20 million share purchase agreement with institutional investor Alumni Capital to further develop its pelareorep drug candidate Pelareorep has shown early-stage success against breast and pancreatic cancer Oncolytics is a biotechnology company focused on cancer immunotherapies Oncolytics Biotech stock has given back 55.97 per cent year-over-year and 66.51 per c…
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by…
Coverage Details
Bias Distribution
- 85% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
